8K Current Report

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): May 15, 2015 (May 12, 2015)


VolitionRx Limited

(Exact name of registrant as specified in its charter)

 

Delaware

000-30402

91-1949078

(State or other jurisdiction

(Commission File Number)

(IRS Employer

of Incorporation)

 

Identification Number)

 

 

 

 

1 Scotts Road

#24-05 Shaw Centre

Singapore 228208

 

 

(Address of principal executive offices)

 

 

 

 

 

Telephone: +1 (646) 650-1351

Facsimile: +32 8172 5651

 

 

(Registrant’s Telephone and Facsimile Number)

 


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

       Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 


       Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 


       Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)


       Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

 




VOLITIONRX LIMITED

Form 8-K

Current Report


Item 2.02. Results of Operations and Financial Condition.


The following information is being “furnished” in accordance with General Instruction B.2. of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing:


On May 12, 2015, VolitionRx Limited hosted a conference call discussing its financial results for the quarter ended March 31, 2015. Furnished herewith as Exhibit 99.1 and incorporated by reference herein is a copy of the transcript of the conference call.


Item 9.01. Financial Statements and Exhibits.


(d)

Exhibits.

 


Exhibit

 

Number

Description of Exhibit

99.1

First Quarter 2015 Financial Earnings and Business Update Conference Call Transcript  dated May 12, 2015(1)


(1)Reference is made to the Exhibit Index hereto with respect to the exhibits furnished herewith. The exhibits listed in the Exhibit Index hereto are being “furnished” in accordance with General Instruction B.2. of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall they be deemed to be incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.





SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


  

VOLITIONRX LIMITED

 

 

Date: May 15, 2015

By:  

/s/ Cameron Reynolds     

  

  

Cameron Reynolds

  

  

Chief Executive Officer & President